Gilead Sciences, Inc., founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative medicines primarily in the areas of antiviral therapies, including treatments for HIV, hepatitis B, hepatitis C, and influenza. Key products include the antiviral drugs Biktarvy, Truvada, and Harvoni, which have made significant impacts in their respective therapeutic areas.
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Gilead Sciences began issuing bonds in 2014, with a notable $1 billion offering to refinance existing debt and finance general corporate purposes. In 2020, Gilead raised $3.25 billion in a multi-tranche bond issuance to support its acquisition of Immunomedics, a pivotal move into oncology. As of October 2023, Gilead's bonds typically yield around 2.50%, comparatively lower than the pharmaceutical industry's average, reflecting investor confidence in its robust product pipeline and financial stability.